Basic information Safety Supplier Related

7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE

Basic information Safety Supplier Related

7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE Basic information

Product Name:
7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE
Synonyms:
  • 7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE
  • 7-Benzyl-9-oxo-3,7-diaza-bicyclo3.3.1none-3-carboxylic acid tert-butyl ester
  • 7-Benzyl-3-Boc-3,7-dizalbicylclo[3.3.1]nonan-9-one
  • tert-butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
  • 7-Benzyl-9-oxo-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
  • 3-Boc-7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane
  • 3,7-Diazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-oxo-7-(phenylmethyl)-, 1,1-dimethylethyl ester
  • tert-butyl (1r,5s)-7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
CAS:
227940-70-7
MF:
C19H26N2O3
MW:
330.42
Product Categories:
  • pharmacetical
Mol File:
227940-70-7.mol
More
Less

7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE Chemical Properties

storage temp. 
2-8°C
Appearance
Off-white to light yellow Solid
More
Less

7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONE Usage And Synthesis

Synthesis

50-00-0

79099-07-3

100-46-9

227940-70-7

To a solution of methanol (20 mL) containing N-tert-butoxycarbonyl-4-piperidone (3 g, 15.06 mmol), benzylamine (1.73 mL, 15.81 mmol), and acetic acid (0.86 mL, 15.06 mmol) was added a suspension of paraformaldehyde (1 g, in 30 mL of methanol) under stirring. The reaction mixture was heated to reflux and stirred for 1 hour, followed by the addition of paraformaldehyde (1 g) and continued stirring for 4 hours. Upon completion of the reaction, the mixture was cooled to room temperature and concentrated. The concentrated residue was dissolved in ether (40 mL) and alkalized by adding 1M potassium hydroxide solution (20 mL). The organic layer was separated and the aqueous phase was extracted four times with ether. The organic phases were combined, dried with anhydrous sodium sulfate for 20 min, filtered and concentrated. The resulting yellow residue was purified by fast chromatography (silica gel 80 g, elution gradient: 0 to 50% ethyl acetate/hexane, 20 min) to afford tert-butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (5 g, 100% yield). lRMS (ESI): m/z Calculated value [M+H]+ 330.19, measured value 362.9 ([M+MeOH]+).

References

[1] Patent: WO2008/55068, 2008, A2. Location in patent: Page/Page column 176-177
[2] Patent: WO2009/137503, 2009, A1. Location in patent: Page/Page column 57-58
[3] Patent: US2017/749, 2017, A1. Location in patent: Paragraph 0558
[4] Tetrahedron, 2015, vol. 71, # 15, p. 2241 - 2245
[5] Chemical communications (Cambridge, England), 2002, # 7, p. 673 - 675

7-BENZYL-3-BOC-3,7-DIAZABICYCLO[3.3.1]NONAN-9-ONESupplier

Chengdu NoVi Biotechnology Co., Ltd.
Tel
028-81458053
Email
novibiotech@163.com sales@novi-biotech.com
EnliPharma Technology Co., Ltd
Tel
0551-66399836 18955197623
Email
sales@enlipharma.com
Nantong MYBio-pharm. Co., Ltd.
Tel
0513-85921823 18662920231
Email
sales@ntminyanmedical.com
Shanghai AQBioPharma Co., Ltd.
Tel
13661411401
Email
yinglv.que@aqbiopharma.com.cn
JW & Y Pharmlab Co., Ltd.
Tel
021-64340559 13651849907;
Email
xinyu_shi@jwypharmlab.com.cn